Request Demo
Last update 15 Jul 2025
Doripenem
Last update 15 Jul 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms Doripenem Hydrate, Doripenem hydrate (JP17), doripenem monohydrate + [9] |
Target |
Action inhibitors |
Mechanism PBPs inhibitors(Bacterial penicillin-binding protein inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Japan (25 Jul 2005), |
RegulationOrphan Drug (United States) |
Login to view timeline
Structure/Sequence
Molecular FormulaC15H26N4O7S2 |
InChIKeyNTUBEBXBDGKBTJ-WGLOMNHJSA-N |
CAS Registry364622-82-2 |
Related
50
Clinical Trials associated with DoripenemCTR20180182
健康受试者中注射用多立培南单剂药代动力学及药代动力学/药效学研究
[Translation] Single-dose pharmacokinetics and pharmacokinetic/pharmacodynamic studies of doripenem for injection in healthy subjects
CTR20170854
评价注射用多立培南治疗复杂性尿路感染患者有效性和安全性的随机、盲法、阳性药平行对照、多中心临床研究
[Translation] A randomized, blinded, positive drug parallel controlled, multicenter clinical study to evaluate the efficacy and safety of doripenem for injection in the treatment of patients with complicated urinary tract infection
CTR20130289
随机、盲法、注射用美罗培南平行对照、多中心试验评价注射用多立培南治疗复杂性尿路感染的安全性和有效性
[Translation] A randomized, blinded, parallel-controlled, multicenter trial of meropenem for injection to evaluate the safety and efficacy of doripenem for injection in the treatment of complicated urinary tract infections
100 Clinical Results associated with Doripenem
Login to view more data
100 Translational Medicine associated with Doripenem
Login to view more data
100 Patents (Medical) associated with Doripenem
Login to view more data
2,046
Literatures (Medical) associated with Doripenem01 Aug 2025MICROBIAL PATHOGENESIS
Inhibitory effect of naringin, naringenin, and crocin on biofilm formation and lecA gene expression in Pseudomonas aeruginosa clinical isolates
Article
Author: Goli, Hamid Reza ; Gholami, Mehrdad ; Sherafati, Sara ; Ebrahimzadeh, Mohammad Ali
Biofilm formation by Pseudomonas aeruginosa is a considerable challenge in treating infections. We aimed to investigate the inhibitory effect of crocin, naringin, and naringenin on biofilm formation capacity and the expression of the lecA gene by this organism. One hundred unrepeated P. aeruginosa isolates were collected from hospitalized patients and were identified. The antibiotic resistance pattern of the isolates was determined using the disk agar diffusion method. The minimum inhibitory concentration (MIC) of naringin, naringenin, and crocin was determined by a micro broth dilution test. Then, the biofilm production ability of the isolates was evaluated before and after treatment with the investigated flavonoids using the microtiter plate test. Finally, the lecA gene expression of the isolates was checked before and after treatment with investigated flavonoids using the Real-time PCR method. Among 89 biofilm-producer isolates, 48 (53.93 %), 17 (19.1 %), and 24 (26.96 %) showed a strong, moderate, and weak biofilm formation ability. Biofilm-positive isolates were more resistant to all tested antibiotics. Also, among 41 multidrug-resistant (MDR) isolates, 33 (80.48 %) were strong biofilm producers (P-value = 0.01). A strong correlation was observed between the lecA gene expression and the biofilm production ability of the isolates (P-value = 0.000). The investigated flavonoids were significantly effective on biofilm production by P. aeruginosa. Among 10 strong-biofilm producers, all (100 %) showed a moderate ability to form biofilm after treatment with crocin (P-value = 0.02), and 6 (60 %) isolates had lost their ability to produce biofilm after treatment with the simultaneous use of crocin with ciprofloxacin or tobramycin (P-value = 0.000). Also, one isolate was grouped as biofilm-negative after treatment with naringin (P-value = 0.012). The crocin, naringin, and naringenin and their concurrent use of antibiotics decreased 2-8-fold of the lecA gene expression in strong biofilm-producer isolates (P-value˂0.05). Crocin, naringin, and naringenin can be used separately or simultaneously with antibiotics to inhibit biofilm and reduce the expression of virulence factors effective in biofilm production in P. aeruginosa.
01 Jul 2025JOURNAL OF INFECTION AND CHEMOTHERAPY
Antimicrobial susceptibility surveillance of bacterial isolates recovered in Japan from odontogenic infections in 2018
Article
Author: Miyake, Minoru ; Hoshi, Kazuto ; Naito, Hiroyuki ; Yamazaki, Hiroshi ; Akashiba, Tohru ; Kiyota, Hiroshi ; Kaneko, Akihiro ; Moridera, Kuniyasu ; Matsumoto, Tetsuya ; Ito, Yoku ; Hasegawa, Naoki ; Terasawa, Fumitaka ; Iwabuchi, Hiroshi ; Kanda, Taku ; Uematsu, Masataka ; Suzuki, Takatsugu ; Kishimoto, Hiromitsu ; Obayashi, Yumiko ; Hanaki, Hideaki ; Busujima, Yasunobu ; Matsumoto, Kazuhiro ; Nakashima, Dai ; Hamada, Tomohiro ; Sato, Junko ; Okamoto, Tetsuji ; Sakamoto, Akihiko ; Izawa, Kazumi ; Abe, Masanobu ; Morihana, Takefumi ; Furudoi, Shungo ; Iseki, Tomio
BACKGROUND:
This study reports the findings of the second antimicrobial susceptibility surveillance study of isolates recovered from odontogenic infections in Japan.
METHODS:
A total of 164 odontogenic infections samples including periodontitis (group 1, n = 33), pericoronitis (group 2, n = 7), jaw inflammation (group 3, n = 83), and phlegmon in the jawbone area (group 4, n = 42) from 21 facilities were included in the study.
RESULTS:
Antimicrobial susceptibility testing was performed on 515 isolates, consisting of 120, 115, 173, 38, and 69 Streptococcus spp., anaerobic gram-positive cocci, Prevotella spp., Porphyromonas spp., and Fusobacterium spp. isolates, respectively. The ratio of susceptible bacteria to causative agents of odontogenic infections was determined in accordance with the guidelines of the Clinical and Laboratory Standards Institute. The susceptibility rates of Streptococcus anginosus were as follows: ampicillin, 98.6 %; cefcapene, ceftriaxone, meropenem, and doripenem, 100 %; clarithromycin and azithromycin, 71.2 %; and clindamycin, 87.7 %. The MIC90 value for ampicillin for Prevotella spp. was 32 μg/mL, with a susceptibility rate of 65.3 %. The MIC90 value for sulbactam/ampicillin was 2 μg/mL, with a susceptibility rate of 100 %.
CONCLUSIONS:
The findings of the present study indicate that the resistance to the combination of penicillins and β-lactamase inhibitors, the first-line antimicrobial agents for odontogenic infections and oral infections caused by anaerobic flora, are low.
13 Jun 2025Future Microbiology
Enhancing colistin efficacy with combination therapies for multidrug-resistant
P. aeruginosa
and
A. baumannii
isolates
Article
Author: Oyardi, Ozlem ; Karaaslan, Elif ; Dosler, Sibel
AIM:
Increasing resistance among ESKAPEEc pathogens, particularly Acinetobacter baumannii and Pseudomonas aeruginosa, has necessitated the use of last-resort antibiotics such as colistin. This study aimed to evaluate the effectiveness and reveal a dynamic picture of colistin-based combination therapies.
MATERIALS & METHODS:
This study evaluated the in vitro efficacy of colistin in combination with doxycycline, doripenem, and rifampicin against multidrug-resistant clinical isolates of P. aeruginosa (n = 23) and A. baumannii (n = 26). Susceptibility testing performed by microbroth dilution method, and synergistic interactions were assessed via checkerboard and time-kill curve (TKC) assays.
RESULTS:
All isolates were resistant to colistin, according to their MICs. In checkerboard assays, according to synergism rates, colistin-doripenem and colistin-doxycycline combinations were particularly effective. The degrees of synergy for doripenem, doxycycline, and rifampicin were 30%, 90%, and 20%, respectively, against P. aeruginosa, and 30%, 60%, and 30%, respectively, against A. baumannii. In TKC analysis, synergistic interactions are generally observed with colistin at 1/4×MIC or 1×MIC, and indifference effects at 4×MIC, similar to colistin monotherapy. TKCs also confirmed the bactericidal activities of combinations that achieved ≥3-log10 reductions in initial bacterial counts.
CONCLUSIONS:
Colistin-based combination therapies, especially colistin-doripenem, may be promising approaches for combating multidrug-resistant pathogens while potentially reducing nephrotoxicity risk.
2
News (Medical) associated with Doripenem100 Deals associated with Doripenem
Login to view more data
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Meningococcal Infections | Japan | 17 Mar 2015 | |
| Paediatric infections | Japan | 10 Apr 2013 | |
| Hospital-acquired pneumonia | European Union | 25 Jul 2008 | |
| Hospital-acquired pneumonia | Iceland | 25 Jul 2008 | |
| Hospital-acquired pneumonia | Liechtenstein | 25 Jul 2008 | |
| Hospital-acquired pneumonia | Norway | 25 Jul 2008 | |
| Pneumonia, Ventilator-Associated | European Union | 25 Jul 2008 | |
| Pneumonia, Ventilator-Associated | Iceland | 25 Jul 2008 | |
| Pneumonia, Ventilator-Associated | Liechtenstein | 25 Jul 2008 | |
| Pneumonia, Ventilator-Associated | Norway | 25 Jul 2008 | |
| Complicated intra-abdominal infection | United States | 12 Oct 2007 | |
| Complicated urinary tract infection | United States | 12 Oct 2007 | |
| Pyelonephritis | United States | 12 Oct 2007 | |
| Gram-Negative Bacterial Infections | Japan | 08 Sep 2005 | |
| Gram-Positive Bacterial Infections | Japan | 03 Sep 2005 | |
| Urinary Tract Infections | Japan | 30 Aug 2005 | |
| Bacterial Infections | Japan | 25 Jul 2005 | |
| Respiratory Tract Infections | Japan | 25 Jul 2005 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Abdomen, Acute | Phase 3 | United States | 01 Dec 2010 | |
| Abdomen, Acute | Phase 3 | Argentina | 01 Dec 2010 | |
| Abdomen, Acute | Phase 3 | Brazil | 01 Dec 2010 | |
| Abdomen, Acute | Phase 3 | Chile | 01 Dec 2010 | |
| Abdomen, Acute | Phase 3 | Colombia | 01 Dec 2010 | |
| Abdomen, Acute | Phase 3 | Latvia | 01 Dec 2010 | |
| Abdomen, Acute | Phase 3 | Lithuania | 01 Dec 2010 | |
| Abdomen, Acute | Phase 3 | Panama | 01 Dec 2010 | |
| Abdominal Abscess | Phase 3 | United States | 01 Dec 2010 | |
| Abdominal Abscess | Phase 3 | Argentina | 01 Dec 2010 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 3 | - | 13 | Doripenem 1 g q8h | jmknbtbfxs(iwpbkgouej) = surwewwxhb ffvzxdanqk (jwoqfbkpsi ) View more | - | 28 Dec 2015 | |
NCT01381848 (Pubmed) Manual  | Phase 1 | 52 | (Neonates (<4 weeks in chronological age)) | txekqvmuvu(kqtvfetcpl) = qqgltmyguy hqwyyfammv (xeuwqjkkbl ) View more | Positive | 01 Aug 2015 | |
(infants >4 weeks.) | txekqvmuvu(kqtvfetcpl) = jiqyifmccy hqwyyfammv (xeuwqjkkbl ) View more | ||||||
Not Applicable | Febrile Neutropenia First line | - | lveehlwlgz(ikydhukkba) = nulnikjmye jfgnzqdmce (cjlaumfniq ) View more | Positive | 21 May 2015 | ||
lveehlwlgz(ikydhukkba) = jvfxsqroon jfgnzqdmce (cjlaumfniq ) View more | |||||||
Phase 3 | 41 | (Doripenem) | evujffxtxf = gqjvyvdbft irlennefor (ithzxkmwqn, ydkqjezmxn - xlanlgqfuy) View more | - | 02 Jul 2014 | ||
(Cefepime) | evujffxtxf = uwiwlpydxq irlennefor (ithzxkmwqn, uxuufudntq - sgvscpjvte) View more | ||||||
Phase 3 | 7 | (Doripenem) | tjwkiymqmd = nphbgtrgfa voduyphcjc (xousvpyhke, aiilujzwgn - vqncijhpvv) View more | - | 02 Jul 2014 | ||
(Cefepime) | tjwkiymqmd = xhhwhglqaq voduyphcjc (xousvpyhke, mahbneymqy - odlqapmfsq) View more | ||||||
Phase 3 | 41 | (Doripenem) | lkxppfzmfi = qllruzizqa gbthvyokhf (mazcqmugto, vbfepelknj - cfazklgbeq) View more | - | 02 Jul 2014 | ||
(Meropenem) | lkxppfzmfi = pfuccrgvio gbthvyokhf (mazcqmugto, akfvnbboiv - domhmpkcdp) View more | ||||||
Phase 4 | 216 | uzrvwyqyyv(cpokklolhz) = xtltmrvfjv couayycjuq (hnjfsztkyx ) View more | - | 01 Apr 2014 | |||
Phase 2 | 185 | ecjhfrtety = cwctyiscfp mgizpsfpgq (rismyyvbzv, eawrmprwqi - ioydfnmwah) View more | - | 25 Sep 2013 | |||
Phase 4 | 216 | (Nosocomial Pneumonia (NP)) | wrpziwsarc = gjhsscecvb ifvfkhfhpd (nqrzhxvkxx, myvtltaozx - bblnpolvap) View more | - | 07 Feb 2013 | ||
(Ventilator-Associated Pneumonia (VAP)) | wrpziwsarc = ubnitfgtcc ifvfkhfhpd (nqrzhxvkxx, apagyyiyuk - oeyjrqdosr) View more | ||||||
Phase 3 | 274 | kavbfkpytm(pxmkwpxlsf) = pukwohrbpx xbhbvdpcso (svnzzmjzsu, -5.0 to 18.5) View more | Negative | 13 Nov 2012 | |||
Imipenem-cilastatin | kavbfkpytm(pxmkwpxlsf) = awzpgqkahq xbhbvdpcso (svnzzmjzsu ) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free